The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Nigericin inhibits the reaction [AQP9 protein results in increased uptake of Lactic Acid]; Nigericin inhibits the reaction [AQP9 protein results in increased uptake of Selenious Acid]
[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] affects the activity of CASP1 protein; [Nigericin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP1 protein; CASP1 protein affects the reaction [Nigericin results in increased secretion of IL1B protein]; dapansutrile affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] affects the activity of CASP1 protein] [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] binds to [CASP1 protein binds to NLRP3 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of CASP1 protein; Arsenic Trioxide inhibits the reaction [Nigericin results in increased cleavage of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] promotes the reaction [CASP1 protein binds to NLRP3 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of CASP1 protein]; sodium arsenite inhibits the reaction [Nigericin results in increased cleavage of CASP1 protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased cleavage of CASP1 protein]]
4-hydroxybenzoic acid inhibits the reaction [[Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of GSDMD protein]; [5-(3-(4-(4-benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl))propanamide co-treated with 4-hydroxybenzoic acid] inhibits the reaction [[Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of GSDMD protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of GSDMD protein; [Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of GSDMD protein; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased cleavage of GSDMD protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased cleavage of GSDMD protein]]
[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL18 protein; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL18 protein]
2-amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-piperidin-4-yl nicotinonitrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL1B protein]; 2-amino-6-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-4-piperidin-4-yl nicotinonitrile promotes the reaction [dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL1B protein]]; 4-hydroxybenzoic acid inhibits the reaction [[Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; 4-hydroxybenzoic acid inhibits the reaction [[Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; 5-(3-(4-(4-benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl))propanamide inhibits the reaction [[Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; [4-hydroxybenzoic acid co-treated with 5-(3-(4-(4-benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl))propanamide] inhibits the reaction [[Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; [5-(3-(4-(4-benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl))propanamide co-treated with 4-hydroxybenzoic acid] inhibits the reaction [[Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Nigericin] results in increased secretion of IL1B protein; [Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Nigericin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; Arsenic Trioxide inhibits the reaction [Nigericin results in increased cleavage of IL1B protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of and results in increased secretion of IL1B protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased secretion of IL1B protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Nigericin] results in increased secretion of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased secretion of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Nigericin] results in increased expression of IL1B protein]; sodium arsenite inhibits the reaction [Nigericin results in increased cleavage of IL1B protein] [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL1B protein; [Nigericin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL1B protein; CASP1 protein affects the reaction [Nigericin results in increased secretion of IL1B protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of IL1B protein]; Disulfiram inhibits the reaction [Nigericin results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [Nigericin results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [Nigericin results in increased secretion of IL1B protein]
NLRP3 protein affects the reaction [Nigericin results in increased secretion of IL1B protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased expression of NLRP3 protein]] [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] binds to [CASP1 protein binds to NLRP3 protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] binds to [PYCARD protein binds to NLRP3 protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] promotes the reaction [PYCARD protein binds to NLRP3 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] promotes the reaction [CASP1 protein binds to NLRP3 protein]]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] promotes the reaction [PYCARD protein binds to NLRP3 protein]]; Nigericin inhibits the reaction [neoisoliquiritin inhibits the reaction [Cadmium Chloride results in increased expression of NLRP3 protein]]
PYCARD protein affects the reaction [Nigericin results in increased secretion of IL1B protein] Nigericin inhibits the reaction [peiminine inhibits the reaction [Particulate Matter results in increased expression of PYCARD protein]] [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] binds to [PYCARD protein binds to NLRP3 protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] promotes the reaction [PYCARD protein binds to NLRP3 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] promotes the reaction [PYCARD protein binds to NLRP3 protein]]; Nigericin inhibits the reaction [neoisoliquiritin inhibits the reaction [Cadmium Chloride results in increased expression of PYCARD protein]]
[lipopolysaccharide, E coli O55-B5 co-treated with Nigericin] results in increased secretion of TNF protein; [Lipopolysaccharides co-treated with Nigericin] results in increased expression of TNF protein
browse the term
